within Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01C_HypothalamicHormones.H01CC04_Linzagolix;

model Linzagolix
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.92,
    Cl = 1.0111111111111111e-06,
    adminDuration = 600,
    adminMass = 200 / 1000000,
    adminCount = 1,
    Vd = 0.0526,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.009333333333333334,
    Tlag = 19.8,
    Vdp = 0.31,
    k12 = 8.055555555555556e-06,
    k21 = 8.055555555555556e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Linzagolix</td></tr><tr><td>ATC code:</td><td>H01CC04</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>200</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>52.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.64</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Linzagolix is an oral, selective, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist used for the treatment of uterine fibroids and endometriosis in women of reproductive age. It reduces estrogen levels by suppressing the hypothalamic-pituitary-gonadal axis. Linzagolix is approved in the European Union but not in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy premenopausal women after oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.H.H01CC04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Linzagolix;
